NETWORKING & COMMUNITY / LATEST NEWS

Do you have important news to share with us? ESGCT members are invited to send their news items to office@esgct.eu to share via our website and social media.

FDA approval of the Biologics License Application (BLA) for Waskyra, the first gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS).

The ESGCT would like to congratulate Fondazione Telethon and HSR-TIGET on the milestone achievement of the FDA approval of WAS ex vivo gene therapy. Please see below their statement: We are honoured to share a moment of profound significance for us, for patients, families, and the scientific community. The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra , the first gene therapy for the treatment of Wiskott-Aldrich

14 minutes ago

2025-SEVILLE

The 32nd ESGCT Annual Congress took place in collaboration with SETGYC from 7-10 October 2025 at Fibes in Seville. Abstracts published by Human Gene Therapy will be available soon. Event Statistics (Click to enlarge) We are very grateful for the support of all our sponsors and partners.

Nov 7

Around the World: Oncology, Hematology, and Cancer-Focused Cell and Gene Therapy in India

Hosted as part of the AROUND THE WORLD SERIES in collaboration with the Coalition of International Gene Therapy Societies.

Jul 7

Claire Booth wins the Rosalind Franklin Society Award

Congratulations to Claire Booth, who received the Rosalind Franklin Society Special Award in Science given by Mary Ann Liebert, Inc. and the Rosalind Franklin Society.

May 6

Fondazione Telethon announces submission of MAA to EMA for Gene Therapy for the treatment of Wiskott-Aldrich Syndrome patients

Read the press release here for full details.

Feb 5